Chronic hepatitis C genotype 1 patients with insulin resistance treated with pioglitazone and peginterferon alpha-2a plus ribavirin (Q42977737)

12 November 2017

Chronic hepatitis C genotype 1 patients with insulin resistance treated with pioglitazone and peginterferon alpha-2a plus ribavirin (English)

1 reference

12 November 2017

1 reference

1 reference

1 reference

1 reference

1 reference

Stephen A Harrison

1

1 reference

12 November 2017

Fayez M Hamzeh

2

1 reference

12 November 2017

Jian Han

3

1 reference

12 November 2017

Prashant K Pandya

4

1 reference

12 November 2017

Muhammed Y Sheikh

5

1 reference

12 November 2017

John M Vierling

6

1 reference

12 November 2017

language of work or name

English

0 references

publication date

11 June 2012

1 reference

12 November 2017

1 reference

12 November 2017

56

1 reference

12 November 2017

464-473

1 reference

12 November 2017

2

1 reference

Insulin resistance and hepatitis C: an evolving story

12 November 2017

1 reference

Association of diabetes mellitus and chronic hepatitis C virus infection.

21 January 2018

1 reference

Association between hepatitis C virus seropositivity, carotid-artery plaque, and intima-media thickening

21 January 2018

1 reference

Insulin resistance is associated with chronic hepatitis C virus infection and fibrosis progression [corrected].

21 January 2018

1 reference

Evidence for a link between hepatitis C virus infection and diabetes mellitus in a cirrhotic population

21 January 2018

1 reference

High prevalence of hepatitis C infection in Afro-Caribbean patients with type 2 diabetes and abnormal liver function tests.

21 January 2018

1 reference

High prevalence of hepatitis C virus infection in diabetic patients

21 January 2018

1 reference

Viral clearance is associated with improved insulin resistance in genotype 1 chronic hepatitis C but not genotype 2/3

21 January 2018

1 reference

Human hepatitis C virus NS5A protein alters intracellular calcium levels, induces oxidative stress, and activates STAT-3 and NF-kappa B.

21 January 2018

1 reference

Hepatitis C virus core protein inhibits mitochondrial electron transport and increases reactive oxygen species (ROS) production

21 January 2018

1 reference

The protein phosphatase 2A represents a novel cellular target for hepatitis C virus NS5A protein

21 January 2018

1 reference

Involvement of the PA28 -Dependent Pathway in Insulin Resistance Induced by Hepatitis C Virus Core Protein

21 January 2018

1 reference

The hepatitis C virus core protein of genotypes 3a and 1b downregulates insulin receptor substrate 1 through genotype-specific mechanisms

21 January 2018

1 reference

Hepatitis C virus core protein upregulates serine phosphorylation of insulin receptor substrate-1 and impairs the downstream akt/protein kinase B signaling pathway for insulin resistance

21 January 2018

1 reference

Clearance of HCV improves insulin resistance, beta-cell function, and hepatic expression of insulin receptor substrate 1 and 2.

21 January 2018

1 reference

Correlation between insulin resistance and hepatitis C viral load

21 January 2018

1 reference

High hepatitis C viral load is associated with insulin resistance in patients with chronic hepatitis C.

21 January 2018

1 reference

Insulin resistance in chronic hepatitis C: association with genotypes 1 and 4, serum HCV RNA level, and liver fibrosis

21 January 2018

1 reference

Insulin resistance impairs sustained response rate to peginterferon plus ribavirin in chronic hepatitis C patients.

21 January 2018

1 reference

Race, insulin resistance and hepatic steatosis in chronic hepatitis C.

21 January 2018

1 reference

Insulin resistance is a major determinant of sustained virological response in genotype 1 chronic hepatitis C patients receiving peginterferon alpha-2b plus ribavirin.

21 January 2018

1 reference

Insulin resistance predicts response to peginterferon-alpha/ribavirin combination therapy in chronic hepatitis C patients.

21 January 2018

1 reference

Whole-body insulin sensitivity index is a highly specific predictive marker for virological response to peginterferon plus ribavirin therapy in chronic hepatitis C patients with genotype 1b and high viral load.

21 January 2018

1 reference

Pioglitazone improves virological response to peginterferon alpha-2b/ribavirin combination therapy in hepatitis C genotype 4 patients with insulin resistance

21 January 2018

1 reference

Pioglitazone in chronic hepatitis C not responding to pegylated interferon-alpha and ribavirin

21 January 2018

1 reference

Pioglitazone as adjuvant therapy in chronic hepatitis C: sequential rather than concomitant administration with pegylated interferon and ribavirin?

21 January 2018

1 reference

Effect of treatment with peginterferon or interferon alfa-2b and ribavirin on steatosis in patients infected with hepatitis C.

21 January 2018

1 reference

Treatment of insulin resistance with metformin in naïve genotype 1 chronic hepatitis C patients receiving peginterferon alfa-2a plus ribavirin

21 January 2018

1 reference

Importance of changes in adipose tissue insulin resistance to histological response during thiazolidinedione treatment of patients with nonalcoholic steatohepatitis

21 January 2018

1 reference

Pioglitazone in the treatment of NASH: the role of adiponectin

21 January 2018

1 reference

Role of serum adiponectin level in the development of liver cirrhosis in patients with hepatitis C virus.

21 January 2018

1 reference

Adiponectin: a new independent predictor of liver steatosis and response to IFN-alpha treatment in chronic hepatitis C.

21 January 2018

1 reference

Reduction of insulin resistance with effective clearance of hepatitis C infection: results from the HALT-C trial

21 January 2018

1 reference

Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance

21 January 2018

1 reference

Interferon-lambda genotype and low serum low-density lipoprotein cholesterol levels in patients with chronic hepatitis C infection.

21 January 2018

1 reference

Beneficial IL28B genotype associated with lower frequency of hepatic steatosis in patients with chronic hepatitis C

21 January 2018

1 reference

IL28B polymorphisms, IP-10 and viral load predict virological response to therapy in chronic hepatitis C.

21 January 2018

1 reference

Non-response to antiviral therapy is associated with obesity and increased hepatic expression of suppressor of cytokine signalling 3 (SOCS-3) in patients with chronic hepatitis C, viral genotype 1

21 January 2018

1 reference

Early changes in natural killer cell function indicate virologic response to interferon therapy for hepatitis C.

21 January 2018

1 reference

Peroxisome proliferator-activated receptor-gamma and its ligands attenuate biologic functions of human natural killer cells

21 January 2018

1 reference

Cellular and molecular changes associated with inhibitory effect of pioglitazone on neointimal growth in patients with type 2 diabetes after zotarolimus-eluting stent implantation

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1002/HEP.25661

1 reference

12 November 2017

1 reference